Engineered immune cells primed with decitabine show promise for tough lymphoma
Disease control
Ongoing
This early-phase trial is testing a new type of immunotherapy for people with B-cell Non-Hodgkin's lymphoma that has returned or not responded to treatment. The therapy uses a patient's own immune cells, which are modified in the lab to target two proteins (CD19 and CD20) on canc…
Phase: PHASE1, PHASE2 • Sponsor: Han weidong • Aim: Disease control
Last updated Jun 26, 2026 19:07 UTC